股东会议事规则 第一章 总则 第一条 为规范广誉远中药股份有限公司（以下简称"公司"）行为，保证股东会 依法行使职权，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民 共和国证券法》（以下简称《证券法》）、《上市公司股东会规则》和《公司章程》的 规定，制定本规则。 第二条 上市公司股东会的召集、提案、通知、召开等事项适用本规则。 第三条 公司应当严格按照法律、行政法规、公司章程及本规则的相关规定召开股 东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当勤勉尽 责，确保股东会正常召开和依法行使职权。 第四条 股东会是公司的权力机构，依法行使下列职权： （一）会议的召集、召开程序是否符合法律、行政法规、上市公司股东会规则和公 司章程的规定； （一）选举和更换非由职工代表担任的董事，决定有关董事的报酬事项； （十三）审议法律、行政法规、部门规章或者公司章程规定应当由股东会决定的其 他事项。 1 （二）审议批准董事会的报告； （三）审议批准公司的利润分配方案和弥补亏损方案； （四）对公司增加或者减少注册资本作出决议； （五）对发行公司债券作出决议； （六 ...

董事会审计委员会实施细则 第一章 总 则 第一条 为进一步提高公司治理水平，规范公司董事会审计委员会的运作，根据《公 司法》《证券法》《上市公司治理准则》《企业内部控制基本规范》《上海证券交易所 股票上市规则》以及《上海证券交易所上市公司自律监管指引 1 号——规范运作》等相 关法律法规及规范性文件的规定，公司特制定本实施细则。 第十条 公司董事会办公室负责审计委员会日常工作联络和会议组织等工作。 第二条 董事会审计委员会是董事会下设的专门委员会，对董事会负责，向董事会 报告工作。 第三条 审计委员会成员应当保证足够的时间和精力履行委员会的工作职责，勤勉 尽责，切实有效地监督、评估公司的内外部审计工作，促进公司建立有效的内部控制并 提供真实、准确、完整的财务报告。 第四条 公司应当为审计委员会提供必要的工作条件，配备专门人员或者机构承担 审计委员会的工作联络、会议组织、材料准备和档案管理等日常工作。审计委员会履行 职责时，公司管理层及相关部门应给予配合。 第二章 审计委员会的人员组成 第五条 审计委员会成员由董事会从董事会成员中任命，由 3 名董事组成，其中独 立董事 2 名，一名为专业会计人士。审计委员会成 ...

证券代码：600771 证券简称：广誉远 编号：临 2025-009 广誉远中药股份有限公司 第八届董事会第十五次会议决议公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广誉远中药股份有限公司（以下简称"公司"）第八届董事会第十五次会议于 2025 年 5 月 23 日以电话、邮件及其他网络通讯方式向全体董事发出通知，于 2025 年 6 月 3 日以通讯方式召开。会议应出席董事 6 名，实际出席董事 6 名，符合《公司法》及《公 司章程》的有关规定。会议由董事长李晓军主持，经认真审议，通过了以下议案： 一、审议通过《关于取消监事会暨修订<公司章程>的议案》 为贯彻落实新《公司法》，进一步提高公司规范化运作水平，根据《上市公司章程 指引》的有关规定，结合公司实际情况，拟取消公司监事会，监事会的职权由董事会审 计委员会行使，并对《公司章程》中相关条款进行修订。 本次取消监事会暨修订《公司章程》的事项尚需股东大会审议，并提请股东大会授 权管理层及经办人员全权负责《公司章程》的工商备案登记手续。股东大会审议通过后， ...

Group 1 - The company has shifted its management approach from "strong control" to "strong operation," emphasizing growth as the primary goal and enhancing operational efficiency [2] - Recent management adjustments have led to a consensus on promoting growth, resulting in improved decision-making and sales performance across various product lines [2] - The company has successfully navigated economic downturns and industry pressures by leveraging strong product efficacy and effective marketing strategies [2] Group 2 - All four core products and business divisions have shown growth, with the An Gong series stabilizing after a decline in 2024, and the Gui Ling Gao regaining its status as a core product [2] - The company is actively addressing the impact of healthcare policies on its products, particularly focusing on optimizing product strategies and enhancing market research [2] - Brand promotion efforts are being intensified through collaborations with authoritative media and research institutions, aiming to enhance marketing effectiveness and academic support for products [2] Group 3 - The company is focused on improving operational quality and market share, with internal performance metrics aligned with growth objectives [3] - The company has established a market value management system in response to regulatory requirements, emphasizing communication with investors and proactive management of stock price fluctuations [3]

Investment Rating - The report indicates a positive outlook for the pharmaceutical and biotechnology industry, suggesting it is at a turning point for profit improvement and has high allocation value [3][4]. Core Insights - The pharmaceutical sector is showing signs of recovery after three years of declining profitability, with a notable increase in net profit margin by 0.3% in Q1 2025 compared to the previous year [3][5]. - Key sub-sectors such as CXO, innovative drugs, biological products, private hospitals, and medical consumables have demonstrated strong performance in Q1 2025, with several leading companies exceeding expectations [3][4]. - The report recommends focusing on sub-sectors and companies with clear upward trends in performance, including innovative drugs and CXO services [3][4]. Overall Performance of the Sector - In 2024, 473 A-share pharmaceutical companies achieved total revenue of 24,588 billion yuan, a year-on-year decrease of 0.9%, and a net profit of 1,412 billion yuan, down 12.1% [3][5]. - For Q1 2025, the sector reported revenue of 6,104 billion yuan, a decline of 4.2% year-on-year, with net profit at 487 billion yuan, down 8.7% [3][5]. Sub-sector Performance - The CXO sector has shown a turnaround since Q4 2024, with Q1 2025 revenue of 225 billion yuan, reflecting an 11.6% year-on-year increase, and net profit of 50 billion yuan, up 72.8% [3][23]. - The innovative drug sector continues to grow rapidly, with leading companies like Heng Rui Medicine and Bai Jie Shen Zhou performing above expectations [3][18]. - The hospital sector is beginning to show signs of recovery, with Q1 2025 revenue of 144 billion yuan, a year-on-year increase of 4.9%, and net profit of 11 billion yuan, up 19.2% [3][28]. Investment Analysis - The report emphasizes the importance of investing in sectors and companies that are showing clear signs of upward trends, particularly in innovative drugs and CXO services [3][4]. - Specific companies recommended for investment include Heng Rui Medicine, Bai Jie Shen Zhou, and Wu Xi AppTec in the innovative drug and CXO sectors [3][4].

证券代码：600771 证券简称：广誉远 编号：临2025-008 广誉远中药股份有限公司 关于参加山西辖区上市公司2025年投资者网上 集体接待日暨年报业绩说明会活动的公告 特别提示 联系人及联系方式如下： 联系人：乔莉 联系电话：0351-7099061 联系传真：0351-7099130 电子邮箱：irm@guangyuyuan.com 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，广誉远中药股份有限公司（以下简称"公司"） 将参加由中国证券 监督管理委员会山西监管局、山西省上市公司协会与深圳市全景网络有限公司联合举办的"山西辖区上 市公司2025年投资者网上集体接待日暨年报业绩说明会"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站（http://rs.p5w.net），或关注微信 公众号：全景财经，或下载全景路演APP，参与本次互动交流，活动时间为2025年5月20日（周二） 14:00-17:00。届时公司高管将在线就公司2024年度业绩、公 ...

证券代码：600771 证券简称：广誉远 编号：临 2025-008 广誉远中药股份有限公司 为进一步加强与投资者的互动交流，广誉远中药股份有限公司（以下简称"公司"） 将参加由中国证券监督管理委员会山西监管局、山西省上市公司协会与深圳市全景网络 有限公司联合举办的"山西辖区上市公司 2025 年投资者网上集体接待日暨年报业绩说 明会"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参与本 次互动交流，活动时间为 2025 年 5 月 20 日（周二）14:00-17:00。届时公司高管将在 线就公司 2024 年度业绩、公司治理、发展战略、经营状况和可持续发展等投资者关心 的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与，并通过电话、邮件等方 式将需要了解的情况和关注的问题提前反馈给公司。 联系人及联系方式如下： 联系人：乔莉 联系电话：0351-7099061 联系传真：0351-7099130 电子邮箱：irm@guangyuyuan.com 关于参加山西辖区上市公 ...

Core Insights - The resurgence of traditional Chinese brands, known as "old national goods," is gaining popularity among younger consumers, driven by a blend of nostalgia and modern innovation [11][12][19] - The 2024 Douyin report indicates that the post-90s generation is the largest group purchasing old national goods, with the post-00s showing a 95% year-on-year increase in orders [11][12] Group 1: Consumer Trends - Young consumers are increasingly drawn to old national goods due to their high cost-performance ratio and emotional connection to traditional culture [13][15] - The integration of modern design elements with traditional craftsmanship is appealing to younger demographics, as seen in brands like Ruifuxiang, which offers customized traditional clothing [14][15] - The rise of "new national tide" reflects a cultural identity that resonates with younger generations, who are willing to pay for products that embody this sentiment [15][19] Group 2: Brand Innovation - Many traditional brands are innovating their product lines to attract younger consumers, incorporating trendy elements and modern marketing strategies [16][20] - Collaborations between established brands, such as the partnership between Guangming Dairy and Guanshengyuan to create the White Rabbit ice cream, have successfully captured the interest of younger audiences [19][20] - The use of digital marketing, including live streaming and short videos, is becoming a key strategy for these brands to engage with younger consumers [21][22] Group 3: Market Expansion - Traditional brands are expanding their market presence by creating unique consumer experiences, such as themed stores and interactive events [17][18] - The integration of cultural elements into marketing strategies is helping brands like Tongqinglou to connect with younger audiences through storytelling and engaging content [22][23] - Government support for intellectual property protection and innovation in traditional brands is expected to enhance their market competitiveness [24]

Group 1 - The core viewpoint of the collaboration between Guangyuyuan and Zhongkang Technology is to enhance brand value, market insights, and product innovation in the high-end traditional Chinese medicine sector [1][3] - The meeting emphasized the importance of cultural empowerment and data-driven strategies to position Guangyuyuan among the top tier of high-end traditional Chinese medicine brands [1][3] - The collaboration aims to leverage Zhongkang Technology's strengths in data analysis and resource integration to optimize product distribution and enhance operational efficiency [3][4] Group 2 - The traditional Chinese medicine market is shifting towards rational and quality-focused consumption, creating opportunities for high-quality brands like Guangyuyuan [3] - Guangyuyuan, with nearly 500 years of history, aims to reconstruct its brand value by focusing on cultural heritage and modern health needs [3][4] - The partnership will explore innovative expressions of traditional Chinese medicine culture, enhancing consumer awareness of heritage craftsmanship [4]

Investment Rating - The investment rating for Guangyuyuan (600771) is not explicitly stated in the provided documents, but the report indicates a positive outlook for the company's performance in 2025 and beyond [2][4]. Core Views - The report highlights that the company achieved better-than-expected performance in Q1 2025, with a revenue increase of 21.48% year-on-year, reaching 417 million yuan, and a net profit increase of 53.94%, amounting to 64 million yuan [2][4]. - The company is expected to reach an operational turning point in 2025, with projected revenues of 1.428 billion yuan, representing a year-on-year growth of 16.9% [6][7]. - The report emphasizes the improvement in operational quality, driven by a strategic focus on growth and the establishment of new partnerships, which has led to an increase in market share and brand recognition [4][7]. Summary by Sections Financial Performance - In 2024, the company reported a revenue of 1.221 billion yuan, a decrease of 4.87% year-on-year, and a net profit of 74 million yuan, down 17.35% year-on-year [2][6]. - The company’s gross margin improved to 73.62% in 2024, up by 0.68 percentage points, despite a decline in net profit due to credit impairment losses [4][6]. - For 2025, the company is projected to achieve a revenue of 1.428 billion yuan and a net profit of 123 million yuan, reflecting a significant recovery and growth trajectory [6][7]. Operational Strategy - The company has adopted a "Four-Dimensional Linkage" strategy to enhance its operational performance, focusing on market development, product quality, brand empowerment, and operational efficiency [4][7]. - The report notes that the company has successfully expanded its network by adding 43 new agents and increasing the total number of retail stores to 462, which supports its growth strategy [4][7]. Future Projections - The forecast for 2025-2027 indicates a steady growth in revenue and net profit, with expected revenues of 1.656 billion yuan in 2026 and 1.927 billion yuan in 2027, alongside net profits of 151 million yuan and 186 million yuan respectively [6][7]. - The projected earnings per share (EPS) for 2025 is 0.25 yuan, with a price-to-earnings (P/E) ratio of approximately 75.51 times [6][7].